title: [Role of somatostatin receptor ligands in the treatment of acromegaly--literature review].
abstract: Acromegaly is a rare disease with typical clinical manifestations. Untreated acromegaly carries a 2-4-fold increase in mortality in long-term outcome. The goal of treatment is double, including biochemical control of the disease (normalization of serum IGF1 levels compared to age and gender matched controls, GH levels below 1 ng/ml after oral glucose load, or random GH below 2.5 ng/ml) and control of the tumor mass. The therapeutic modalities currently available for the treatment of acromegaly are: surgery, medical therapy, radiation therapy and their combinations. The cornerstones of medical therapy in acromegaly are the somatostatin receptor ligands due to their effectiveness in controlling GH excess in 60-70 % of patients and their beneficial effects on tumor volume. Somatostatin analogues have an established role as adjuvant therapy after non-curative surgery, and evidence suggests their use as primary treatment for selected patients. The long-term use of somatostatin receptor ligands is safe and they are well tolerated. Future medical therapy consists of pasireotide, a novel, universal somatostatin receptor agonist, and a new class of drugs named dopastatins. The latter so-called chimeric molecules have strong affinity for somatostatin receptors and dopamine-2 receptors, resulting in a more effective blocking of GH secretion, according to preliminary data. The authors of this paper review the current medical therapy of acromegaly, focusing on the role of somatostatin receptor ligands.
authors.affiliation: Pécsi Tudományegyetem, Klinikai Központ I. Belgyógyászati Klinika Pécs Ifjúság u. 13. 7624.
authors.forename: Orsolya
authors.initials: O
authors.lastname: Nemes
authors.forename: Emese
authors.initials: E
authors.lastname: Mezosi
mesh_terms: D000172:Acromegaly / Q000188:drug therapy* / Q000378:metabolism; D000236:Adenoma / Q000378:metabolism / Q000628:therapy; D016022:Case-Control Studies; D004298:Dopamine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D019382:Human Growth Hormone / Q000037:antagonists & inhibitors*; D006801:Humans; D008024:Ligands; D008297:Male; D010911:Pituitary Neoplasms / Q000378:metabolism / Q000628:therapy; D017481:Receptors, Somatostatin / Q000819:agonists* / Q000378:metabolism*; D013004:Somatostatin / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D008024:Ligands; D017481:Receptors, Somatostatin; D019382:Human Growth Hormone; D013004:Somatostatin; C094573:somatostatin receptor 5; C517782:pasireotide; C531242:TBR-760; D004298:Dopamine